Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in the Treatment of Medical Refractory Spastic Esophageal Disorders

Trial Profile

Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in the Treatment of Medical Refractory Spastic Esophageal Disorders

Withdrawn prior to enrolment
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Oesophageal disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jan 2018 Status changed from recruiting to withdrawn prior to enrolment.
    • 05 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 29 Aug 2016 Status changed from recruiting to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top